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Objectives: This article addresses the clinical role for ziprasidone used adjunctively with 
a mood stabilizer in maintenance treatment of bipolar disorder. This review also addresses 
the strengths and limitations of design features in adjunctive studies of second-generation 
antipsychotic drugs added to mood stabilizers.
Methods: The principal study relevant to this review enrolled subjects who were $18 years of 
age, experiencing a recent or current manic or mixed bipolar I episode, with at least moderately 
severe current manic symptoms. To meet criteria for randomization to 6 months maintenance 
treatment, patients had to have failed a short course of treatment with either lithium or valproate 
and achieved benefit with added ziprasidone for 8 consecutive weeks.
Results: Time to intervention for a new mood episode as well as time to discontinuation for any 
reason was significantly longer with adjunctive ziprasidone treatment than with monotherapy 
treatment with mood stabilizer. Three dosages of ziprasidone augmentation were studied. 
Patients treated with 120 mg/day had better efficacy and overall outcomes than did patients 
who received 80 or 160 mg/day of ziprasidone.
Conclusions: Good evidence exists that adjunctive ziprasidone will likely provide greater 
overall efficacy coupled with good tolerability for at least a 6-month period than a strategy of 
continued monotherapy with a mood stabilizer. Changes in open phases of maintenance   studies 
to reduce study enrichment, in study endpoints, and in statistical approaches to analysis of data 
are warranted.
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This review addresses the effectiveness and pragmatic clinical role for ziprasidone 
used adjunctively with a mood stabilizer (MS, lithium or valproate) in maintenance 
treatment of bipolar disorder. The review also addresses the strengths and limitations 
of the unique design features in adjunctive studies of second-generation antipsychotic 
(SGA) drugs added to mood stabilizers. Since the turn of the millennium, four studies 
in bipolar disorder of antipsychotic + mood stabilizer vs mood stabilizer monotherapy 
relapse prevention have been completed. Each study required predefined evidence of a 
syndromal episode at the time of enrollment, or within the prior several months. Three 
required that patients prospectively treated with lithium or valproate for 2 weeks have 
failed to benefit manic, or in one study, manic or depressive symptomatology.1–3 Each 
required a period of treatment with the SGA of interest added openly to continued 
MS, resulting in a portion of enrolled subjects meeting criteria for remission who then 
constituted the sample for the randomized, blinded maintenance trial. The data sets 
were all principally analyzed with Wilcoxon or log-rank life table methods.4 No studies 





other medications required to manage bipolar patients, which 
would be of interest since bipolar disorder patients take a 
median of 3 medications for optimal outcomes.5 Studies and 
guidelines indicate that combination regimens have become 
standard care in the treatment of the majority of patients with 
bipolar disorder.6–10
The ziprasidone adjunctive maintenance study, along 
with two quetiapine studies, are the first to address con-
cerns by the US Food and Drug Administration (FDA) that 
earlier maintenance trials conducted for purposes of a new 
indication have had insufficient symptomatic stabilization 
during an open phase to yield reliable and pragmatically 
useful data on relapse prevention. The ziprasidone study is 
the first to limit the use of adjunctive medication to MS for 
the last 4 weeks of the required period of stabilization to the 
drug of research interest.
Synopsis of important features  
of the study design
Subjects were $18 years of age, experiencing a recent 
or   current manic or mixed bipolar I episode, with current 
symptom severity per the Mania Rating Scale of $14, 
including having scores $2 on $4 items. Subjects were 
outpatients, except that patients hospitalized at the screening 
visit could be enrolled if sufficiently stable for outpatient 
management within approximately 5 days. Lorazepam 
at #2 mg/day for anxiety or insomnia for #4 days a week, 
or a similar drug was permitted. Subjects were excluded 
who had $8 mood episodes over the previous 12 months, 
mental retardation, organic brain syndrome, substance-
induced psychotic disorder or behavioral disturbance within 
2 months of screening, substance abuse/dependence, treat-
ment resistance to $2 other antipsychotic medications, were 
treatment resistance or intolerant to ziprasidone, or were at 
risk of harm to themselves or others. These criteria were 
established to reduce heterogeneity but also to allow most 
persons with manic bipolar I syndromal symptomatology 
into the study, thereby improving generalizability of results. 
Consented subjects first received either lithium or valproate 
at a therapeutic serum concentration (lithium 0.6–1.2 mEq/L 
or valproate 50–125 µg/mL) for $2 weeks, as selected by 
the study psychiatrist. Those still meeting inclusion criteria 
were then entered into the open phase of the study for up 
to 16 weeks during which ziprasidone was added at one of 
three dosages: 80, 120, or 160 mg/day to the MS regimen. 
Subjects whose Clinical Global Impressions-Improvement 
scale (CGI-I) scores were #3 for 8 consecutive weeks, with 
allowance for a CGI-I score $4 at no more than one visit 
were entered into the randomized, blinded maintenance 
phase. The study design required   systematic tapering of 
ziprasidone by 20 mg twice per day every 2 days for subjects 
  randomized to lithium or valproate plus placebo. The study 
was conducted at 98 centers internationally, with 584 subjects 
entering and receiving treatment in the open phase and 127 
randomized to ziprasidone plus MS compared with 113 to 
placebo plus MS in the maintenance phase, yielding an open 
stabilization phase completion rate of 41.1%. For subjects 
randomized to lithium or valproate plus placebo, ziprasi-
done was systematically tapered off by 20 mg twice per day 
every 2 days. Eighty-four of the 127 ziprasidone plus MS 
subjects (66.1%) completed the 6-month randomized phase 
compared with 54 (48.2%) in the placebo plus MS group, 
which comprised 112 who received treatment, yielding an 
overall randomized phase completion rate of 57.7%. Addi-
tional details of inclusion/exclusion criteria, interventions 
and analytical methodologies are provided in the primary 
publication of the study results.3
Efficacy and effectiveness
The primary efficacy endpoint, time to intervention for 
a mood episode, was statistically significantly longer for 
ziprasidone plus MS than MS plus placebo (P = 0.0104). 
Intervention for a mood episode was required by 19.7% of 
subjects receiving ziprasidone, compared with 32.4% of 
subjects receiving placebo. The median time to intervention 
for a mood episode was longer for ziprasidone plus MS 
than MS alone (43.0 days vs 26.5 days) among subjects who 
required an intervention for a mood episode (n = 61). Time 
to discontinuation for any reason also significantly favored 
the adjunctive group ziprasidone (P value = 0.0047). These 
findings were driven by ziprasidone plus mood stabilizer 
preventing manic/mixed more than depressive recurrence.
Among the subset of 106 lithium-treated subjects, the 
proportion of subjects who required intervention for a mood 
episode for ziprasidone plus lithium was 21.1%   compared 
with 44.9% (P = 0.0024) for placebo plus lithium. In 
  contrast, among the 133 valproate-treated subjects, 18.6% of 
  ziprasidone plus valproate subjects required an   intervention 
compared with 22.6% (P = 0.4863) of placebo plus valproate 
subjects.
Post hoc analyses for time to intervention for episodes 
by dose group of ziprasidone indicated that the 120 mg/day 
group was both more efficacious and associated with greater 
persistence with treatment than either the 80 or 160 mg/day 
groups. Rates of intervention for a mood episode for 80 mg, 
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and 25.9%, compared with 32.4% for the placebo plus MS 
group. Only the 120 mg/day group was superior to placebo 
(P = 0.004). Similarly, for discontinuation for any reason, the 
rates for 80 mg, 120 mg and 160 mg/day respectively were 
41.7%, 20%, and 37% and for the placebo plus MS group, 
51.4%. Only the 120 mg/day group was significantly superior 
to placebo (P = 0.001).
Tolerability
For adverse events that occurred at .5% in either randomized 
treatment group, excluding weight change and prolactin 
levels, tremor was the only adverse event that occurred at 
a higher incidence in the ziprasidone plus MS treatment 
group (6.3% vs 3.6%). Rates for serious adverse events and 
for adverse events leading to discontinuation did not differ 
significantly between the two treatment groups.
Weight change was minimal during the open stabilization 
phase. Increase in weight $7% occurred in 5.5% of subjects; 
rates for a $7% decrease in weight were 3.2%. Similarly, 
over the 24 weeks of double-blind treatment, mean weight 
changes in the ziprasidone plus MS group were -0.8 kg 
(SD = 4.8) and +0.5 kg (SD = 4.9) in the placebo plus MS 
group, and the rate of at least 7% weight gain was 5.6% in 
completers for both groups.
Levels of fasting glucose, total cholesterol, low-density 
lipoprotein cholesterol, high-density lipoprotein cholesterol, 
and triglycerides did not change significantly in either 
randomized treatment group. Prolactin levels were elevated 
in 12.3% of ziprasidone plus MS subjects compared with 6% 
of placebo plus MS subjects. During the open phase, mean 
QT interval values at baseline and week 16 were 383.2 ms 
(range, 295.3–476.3) and 390.3 ms (range, 308.0–473.0). 
In no subject was the QTc interval $500 ms. At week 24 of 
the randomized phase, QTc interval did not differ between 
the 2 treatment groups (ziprasidone plus MS: 386.2 ms vs 
placebo plus MS: 378.8 ms, with no values $500 ms in 
either group).
Critical appraisal and 
recommendations for adjunctive 
ziprasidone use in maintenance 
treatment of bipolar disorder
For bipolar I patients who continue to experience inadequate 
control of manic or mixed symptomatology with lithium or 
valproate therapy, this study yields evidence that addition of 
ziprasidone will be likely to provide greater overall efficacy 
and effectiveness for at least a 6-month period than a strategy 
of continued monotherapy with MS. Although not powered 
to test separately the benefit of adjunctive ziprasidone with 
lithium and valproate, the results indicate that adjunctive 
  benefit is substantially greater with lithium than with val-
proate, consequent to worse performance for monotherapy 
lithium than monotherapy valproate. The study has sugges-
tive indications that dosing of ziprasidone at 120 mg/day 
is both more efficacious, and as well tolerated, than either 
lower (80 mg/day) or higher (160 mg/day) regimens. Of note, 
two flexible dose studies of ziprasidone in monotherapy use 
reported that end-of-treatment mean dosages for ziprasidone 
were just over 120 mg/day.11,12
The study provides strong evidence that the   adjunctive use 
of ziprasidone with either lithium or valproate in maintenance 
treatment of adults is well tolerated. In contrast with   consistent 
evidence of weight gain, worsening of lipid profiles, and of 
glucose dysregulation with monotherapy or adjunctive use 
of olanzapine4,13 or quetiapine,1,2 ziprasidone did not appear 
to worsen any of these parameters either during the open or 
randomized phases of the study. Thus, pooling the results 
of the two recent adjunctive (added to lithium or valproate) 
quetiapine studies, quetiapine plus mood stabilizer yielded 
at least 7% weight gain in 23.6% of subjects during the open 
stabilization phase and 9.4% during the randomized phase. 
The analogous rates with ziprasidone plus mood   stabilizer 
in the current study were 5.5% and 5.6%.
Early acute phase studies raised concerns that ziprasidone 
might pose risks for cardiac dysrhythmias.3 The adjunctive 
maintenance study reviewed here, which of course has 
the advantage of yielding relatively long-term data (the 
mean time in study combining both the open phase and the 
  randomized was over 200 days in both treatment groups), 
does not indicate any increase in risk for such adverse effects. 
To date, adjunctive maintenance studies in bipolar disorder 
with other second-generation antipsychotic drugs have not 
been published.
The study design has several important strengths 
that improve confidence in the results. The design of the 
trial, although intended to yield an enriched sample of 
nonresponders to lithium or valproate as monotherapy 
for a bipolar I manic or mixed episode, provided a more 
generalizable sample than other published adjunctive regimen 
trials in bipolar disorder that utilize failure of response in an 
open phase to select randomized phase subjects.13 The study 
design required systematic tapering of ziprasidone by 20 mg 
twice per day every 2 days for subjects randomized to lithium 
or valproate plus placebo. This step, plus that of requiring an 
extended period of symptomatic and functional stability, likely 





of the 24-week study both in the ziprasidone plus MS group 
and the placebo plus MS group. The rate of randomized study 
completion (57.7%) is higher in the ziprasidone adjunctive 
study than any other published adjunctive, blinded, random-
ized trial in bipolar disorder published in this decade. For 
example, pooling the results of the two recent adjunctive 
(added to lithium or valproate) quetiapine studies, quetiapine 
plus mood stabilizer yielded a rate of randomized phase study 
completion of 39.2%.   Additionally, visual inspection of the 
survival curves in the respective published adjunctive studies 
suggests that high early rates of relapse associated with with-
drawal of the adjunctive medication at the end of the open 
phase was less a factor in the ziprasidone study, consequent 
to its design features.
The ziprasidone study has several limitations that 
psychiatrists should consider in applying its results toward 
patients in standard clinical practice. The comparison was 
made in the maintenance treatment of adults with a manic or 
mixed episode of bipolar I disorder. The study therefore does 
not provide guidance on adjunctive use of ziprasidone in still 
symptomatic bipolar depressed patients, or patients younger 
than 18 years of age. Although no bipolar II patients were 
studied, in the opinion of the author, if a bipolar II patient 
treated with lithium or valproate presented with continuing 
hypomanic/manic symptomatology, the findings in this study 
provide some support that adjunctive addition of ziprasidone 
would be an evidence-based action.
A significant source of enrichment from other adjunctive 
study designs has revolved around subjects who experienced 
intolerable side effects or lack of efficacy, both of whom 
were excluded from randomization.2,4,10 In the ziprasidone 
adjunctive study, based on the low rates of adverse effects and 
the relatively high proportion of open phase treated patients 
who met the criteria for response and were randomized, even 
given the requirement for a sustained period of overall good 
clinical status, the enrichment favoring the ziprasidone group 
would appear to be minimal in this regard.
Implications of the ziprasidone 
adjunctive study for future study 
designs in maintenance treatment 
of bipolar disorder
Clinical trial designs for maintenance applications in bipolar 
disorder studies have largely repeated use of several design 
features that have limited generalizability of results and under-
emphasized issues of safety and tolerability. The ziprasidone 
adjunctive design and several other recently published 
adjunctive studies in bipolar disorder provide a basis for 
recommending approaches which will improve generalizability 
of results to real life settings, yield more effectiveness data, 
and facilitate public health and regulatory body actions in 
response to new study data. The aspects briefly addressed 
here are not mutually exclusive, but sufficiently distinct 
to treat individually: subject inclusion/exclusion   criteria, 
open phase methods, duration of required improvement for 
randomization, endpoints and primary outcome measures 
in maintenance phase, duration of maintenance phase, and 
statistical approaches applied in analysis of data.
Subject inclusion/exclusion criteria
Studies will only be applicable to the types of illness states that 
are eligible for enrollment. In bipolar disorder, this essentially 
means deciding whether to require that the patient has 
current syndromal level illness, or that some recent episode 
will suffice. Studies that require only an episode within a 
6-month period, for example, risk enrolling subjects without 
typically active illnesses, therefore weakening possibilities 
for identifying a bona fide efficacious intervention vs 
placebo.14–16 Requirement for a threshold level severity of 
manic and/or depressive symptomatology, as required in the 
ziprasidone study (manic symptomatology), can adequately 
assure severity of illness. Although from a clinical perspective 
enrollment of patients in all phases of bipolar illness might 
seem desirable, if a regimen of interest only has evidence of 
benefit for a certain component of the several major domains 
of bipolar disorder, it is reasonable to limit enrollment to 
patients with symptomatology in that domain or domains.
Open phase methods
To date, only one published maintenance study has utilized 
a design of allowing or requiring open phase treatment to 
include either of the treatments to which patients might be 
randomized in the maintenance phase.17 Such design allows 
a test of the question of whether continuation in maintenance 
of the regimen which was effective acutely is an effective 
strategy. One design strategy that would effectively reduce 
or eliminate enriching a randomized maintenance for one 
regimen would be to make the decision as to randomized group 
at the point of acute phase lead in treatment. One concern 
that has influenced lack of commitment to such a design is 
that the number of acute phase subjects would be expanded, 
since a lower proportion on a less effective regimen would 
become eligible for randomization, thereby increasing costs 
and duration of study. The ziprasidone study had one element 
of continuation of open phase treatment, in that randomized 
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they became eligible for the maintenance phase. This feature 
allowed a meaningful secondary analysis of effectiveness of 
the respective dosages, thereby benefiting generalizability 
to address important clinician questions regarding optimal 
dosing strategies.
Duration of improvement required  
for randomization
The FDA has publically expressed expectations that a 
sustained period of open, acute phase improvement be 
required for eligibility for maintenance studies in bipolar 
disorder. One major basis for such concerns is that a brief, 
even point in time improvement will often be clinically 
meaningful, but will not establish that the patient has 
recovered from the clinical state at admission. Therefore, 
inclusion of such patients will lead to very early relapse 
in the randomized phase following discontinuation of the 
effective drug or regimen of the open phase. The 8 weeks 
of stabilization required in the ziprasidone study, carefully 
designed to also utilize the CGI-I score for randomization, 
appears to have been a successful strategy to address such 
concerns. Desirably, it also did not result in a low rate of 
open phase subjects meeting criteria for randomization. It 
also appears to have yielded a randomized sample that tested 
relapse prevention, rather than a substantial proportion of 
patients with re-exacerbation of an inadequately treated 
entering episode.
Study endpoints
As noted earlier, single point in time endpoints, such as 
time to intervention for an episode, as employed in the 
ziprasidone study and many other maintenance trials in 
bipolar disorder, differ substantially from usual clinical 
care, in which psychiatrists are likely to continue treatment 
through exacerbations in symptomatic severity, even when 
meeting criteria for a depressive or mixed episode, generally 
by increasing frequency of visits and adjunctively modifying 
drug regimens.8 The ziprasidone design, despite principally 
utilizing such a single point in time endpoint, did succeed in 
maintaining a desirably large proportion of randomized in the 
randomized, blinded phase. One consequence of such desired 
persistence is that several of the features of Wilcoxon and log-
rank analyses, eg, describing median time to development of a 
new episode, are generally inapplicable, since the proportions 
of subjects in at least one study arm will not reach as high 
as half of the sample. The application of logistic regression 
analyses and mixed effect repeat measure techniques, which 
take advantage of all time point assessments, provides a 
well established and clinically relevant alternative to time 
to event analyses.
Duration of maintenance phase
Monotherapy maintenance trials have generally been planned 
for 12 to 18 months of randomized treatment. However, in all 
instances, the actual time in study, by all measures, has been 
substantially shorter than that. Even with little evidence that 
withdrawal phenomena impacted rates of new episodes in 
this trial, the majority of endpoints occurred within the first 
half of the 6-month period of maintenance. Most studies have 
reported completion rates below 30% even for the treatment 
arm with the best results. The ziprasidone study indicates that 
a 6-month randomized period will capture most outcome 
information needed to establish evidence for efficacy and 
safety of a regimen.
Statistical approaches
Kaplan–Meier survival analytic techniques which have been 
almost the sole analytic approach in not only adjunctive but 
also monotherapy studies in maintenance treatment of bipolar 
disorder do have utilities. They take into consideration time 
to a targeted outcome and can be conducted to improve 
sensitivity when most actions of interest occur early in a trial, 
or alternatively, late in the course of interventions. However, 
the assumption that all subjects will eventually have the 
endpoints taken as primary outcome measures is generally 
invalid. Further, except indirectly in survival analyses for 
discontinuation for any reason, it is difficult to identify and 
incorporate in an overall analysis the tolerability and adverse 
effects of a treatment. As is evident in the ziprasidone study, 
the desirable objective of retaining a high proportion of 
patients in a trial to study end can result in inability to report 
results as median time to event, both because, as noted earlier, 
some subjects will never have the event and the rates for the 
event may not reach the useful 50% median change from 
baseline. Finally, survival analyses do not deal adequately 
with missing data, which becomes critically important if 
over 15% of subjects enrolled do not complete a study. 
Mixed effects repeated measure techniques (MERM) are 
not a new technique, but with extensions of these techniques 
over the past decade their use has increased dramatically 
for longitudinal clinical trials.18 None of the maintenance 
studies in bipolar disorder published since 2000 has utilized 
MERM techniques. Because nonignorable missingness9 is 
highly likely in all monotherapy longitudinal trials in bipolar 
disorder, and with very low rates of subjects in all treatment 
arms completing these trials, MERM techniques offer Neuropsychiatric Disease and Treatment
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important clarifications over survival techniques. Hedeker 
and Gibbons19 provide a detailed overview of approaches to 
this issue, including assessment of the pattern of missingness. 
One particularly interesting analysis option allows a blend-
ing of survival and MERM analyses that models dropout 
and longitudinal trajectories in a “shared parameter” model 
that integrates information about dropout with the outcome 
trajectory prior to dropout. Another novel approach is a form 
of cluster analysis that identifies groups of patients with simi-
lar symptom trajectories over time. Such techniques would 
be relevant to a study with the design features and outcome 
characteristics of the ziprasidone study.
Conclusion
The adjunctive ziprasidone study in bipolar disorder pro-
vides pragmatic, reliable guidance to clinicians regarding 
why, when, and how to utilize such treatment in an overall 
therapeutic approach in management of bipolar disorders. 
The study has advantages of clear design, relatively high 
retention of subjects, clear outcomes in most areas of analy-
sis, and also serves as a catalyst to consider limitations of 
current methodologies in maintenance trial design and alter-
native methods that can overcome such limitations.
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